National Research Network 2012 Benchmark Report
|
|
|
- Jeffrey French
- 6 years ago
- Views:
Transcription
1 National Research Network 212 Benchmark Report The National Research Network 212 Benchmark Report pulls together real world performance data from hospitals, universities and government agencies across the National Research Network. It is provided as a service to the human subject research community to assist organizations as they benchmark internal performance. The 212 Benchmark Report includes data sampled from April 211- March 212. IRBNet A WIRB-Copernicus Group Company Copyright Protected 213
2 Background Na$onal Research Network 212 Benchmark Report The Na'onal Research Network 212 Benchmark Report assembles real world performance data from hospitals, universi'es and government agencies across the Na'onal Research Network (NRN). It is provided as a service to the human subject research community to assist organiza'ons as they benchmark internal performance. The 212 Benchmark Report includes data from more than 1 randomly selected IRBs ac've on the Na'onal Research Network, sampled from April March 212. Anonymous selec'on was based upon tenure, volume of ac'vity, ins'tu'onal profile, completeness of data and other factors. If you have benchmark report ques'ons, comments, or want to discuss your ins'tu'on's performance, please contact the IRBNet Analy'cs team at benchmark@irbnet.org.
3 About the Data: Ins$tu$onal Research Profile 6% of analyzed research is biomedical in nature; hospitals and universi$es report varied research focus. Overall Profile: 58% Biomedical biomedical: non-oncology 22% social / behavioral 42% biomedical: oncology 36% Hospital Profile: 85% Biomedical biomedical: non-oncology 34% social / behavioral 15% biomedical: oncology 51% University Profile: 8% Social/Behavioral biomedical: non-oncology 6% biomedical: oncology 14% social / behavioral 8% N = 94 N = 56 N = 38 National Research Network 212 Benchmark IRBNet A WIRB-Copernicus Group Company 213
4 Days to and Approval by Type 32% of total $me to first approval by convened review is due to inves$gator errors, omissions and response to commilee decisions (4% for expedited reviews). Days to and First Approval Convened : Submission to 47.5 Convened : Submission to Initial Approval 15.2 Expedited : Submission to 35. Expedited : Submission to Initial Approval 14. Exempt : Submission to Determination Administrative and Expedited / Convened Response to Committee Decisions Errors / Omissions Includes multiple submissions when 2 2 Errors / Omissions and investigator required to obtain initial approval. responses less than.1 National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
5 Convened Total convened review $mes are similar across categories; universi$es issue post- review lelers in 6 days Convened Time to Letter After Decision to Decision Administrative Pre Average Hospital University Biomedical Social / Behavioral Errors / Omissions National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
6 Days to First Approval by Type Hospitals approve new studies via convened review at a faster rate than the NRN average. Days to First Approval 6 5 Convened Time to First Approval Administrative Pre- and Convened Response to Committee Decisions Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
7 Number of Submissions to Obtain Ini$al Approval (Convened ) 82% of studies approved by convened review required two or less submissions to obtain ini$al IRB approval. Number of Submissions to Obtain Initial Approval number of submissions % National Research Network 212 Benchmark Report Convened 82% 95% 99% 1% submissions 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % % approved IRBNet A WIRB-Copernicus Group Company 213
8 Expedited On average, 38% of the $me to complete expedited review is consumed by inves$gator rework of errors and omissions. 25 Expedited Time to Letter After Decision Administrative/ Expedited Rework due to Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
9 Expedited NRN Members complete expedited reviews in 15 days on average. Expedited Expedited Average New Continuing Other National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
10 Expedited Errors and omissions average 7 days for new and con$nuing reviews Expedited New and Continuing Time to Letter After Decision Administrative Pre- and Expedited Rework due to Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
11 Days to First Approval by Type Hospitals approve new studies via expedited review at a faster rate than the NRN average. Days to First Approval Expedited - Time to First Approval Administrative Pre- and Expedited Response to Expedited Decisions Errors / Omissions Average Hospital University Biomedical Social / Behavioral National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
12 Staffing and Workload NRN members efficiently manage large protocol workloads, with an average of less than 2 Staff FTEs. Staffing and Protocol Workload Average Number of Protocols Average Number of IRB Staff (FTE) Protocols per FTE Ins$tu$ons with 1-5 Ac$ve Protocols (Expedited, Convened) Ins$tu$ons with 51-2 Ac$ve Protocols (Expedited, Convened) National Research Network 212 Benchmark Report IRBNet A WIRB-Copernicus Group Company 213
13 IRBNet A WIRB-Copernicus Group Company If you would like to automa$cally receive future copies of Na$onal Research Network Benchmark Reports please submit your request to benchmark@irbnet.org.
National Research Network 2011 Benchmark Report
National Research Network 211 Benchmark Report The National Research Network 211 Benchmark Report pulls together real world performance data from hospitals, universities and government agencies across
Clinical Trial Billing Compliance at UAB
Clinical Trial Billing Compliance at UAB Carolyn P. Whitmire, MBA, CHRC Director, Research Implementa?on Co- Administra?ve Director, Clinical Trials Office UAB Infrastructure Campus and Health System are
2013 Metrics on Human Research Protection Program Performance
2013 Metrics on Human Research Protection Program Performance Updated August 1, 2014 About the Metrics Improving the quality of human research protection programs (HRPP) is a top priority of AAHRPP. Effective
Iden'ty and Access Management Governance
Iden'ty and Access Management Governance Real world prac'ces that work in Higher Educa'on Roopa Chowbey Manager, Iden'ty management 1 Agenda Background Iden'ty and Access Management (IAM) program at George
I R B N E T I N T E R V I E W S E R I E S
Paul Garfinkel MSH, CIP Paul Garfinkel is the Director of the Office of Human Subject Protection for Nemours, as well the Institutional Official. He has held this position since 2004, and has 32 years
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in
Research Compliance Committees
Research Compliance Committees Ephy Khaemba, International Livestock Research Institute ILRI. Laboratory Management & Equipment Opera5ons Workshop. 1 Course Outline Structure of Regulatory Environment
Human Research Participant Protection Program Institutional Review Board (IRB)
Human Research Participant Protection Program Institutional Review Board (IRB) Procedure 1: Determining whether a research activity needs IRB review and approval 1. Subject All research activities that
Can You S)ll Be an Individual? Brian Kahan, D.O. FAAPMR, DAOCPMR, DABIPP The Kahan Center for Pain Management
Can You S)ll Be an Individual? Brian Kahan, D.O. FAAPMR, DAOCPMR, DABIPP The Kahan Center for Pain Management www.thekahancenter.com Learning Objec)ves Developing survival strategy Establish recruitment
Aspects of IBCs in Multicent Multicen er t Clinical Trials Daniel Kavan Kava agh, PhD
Aspects of IBCs in Multicenter Clinical Trials Daniel Kavanagh, PhD Disclosure DGK is employed by WIRB Copernicus Group, a provider of externally administered IBC Services. About Me Senior Director, Biosafety
Human Subjects Research. Kelley A. O Donoghue, MPH, CIP Director Office for Human Subject Protection
Human Subjects Research Kelley A. O Donoghue, MPH, CIP Director Office for Human Subject Protection kelley_odonoghue@urmc.rochester.edu Belmont Report Respect for Persons (Autonomy) Informed Consent Protect
Landscape Analysis of CRISPR-Cas9. An analysis of patent publica1ons and literature in the CRISPR-Cas9 technology space
Landscape Analysis of CRISPR-Cas9 An analysis of patent publica1ons and literature in the CRISPR-Cas9 technology space 2 Objec:ve and Scope This study focuses on the nature of patent and non-patent literature
Investigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
Final Outcome of ASW Symposium
Symposium on the ASEAN Single Window and National Single Windows Borobudur Hotel, Jakarta, Indonesia 18 September 2012 Summary of Session 5 Final Outcome of ASW Symposium 1 ü The current ASW architecture
Tools, Templates, and Checklists for Streamlining IRB Protocol Review
Tools, Templates, and Checklists for Streamlining IRB Protocol Review Sharon Freitag, BSc Megan Kasimatis Singleton, JD, MBE, CIP May 5, 2016 Welcome! Nora Murphy Online Learning Coordinator PRIM&R 1 Content
University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX)
University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX) Ethics and Human Subject Protections Presented by: Olusola Ewulo, M.S. Director,
SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
Strategic Plan
2016 2020 Strategic Plan Mission NJVOAD s mission is to bring together New Jersey organiza9ons ac9ve in disaster assistance, and to foster coopera9on and coordina9on in preparedness, response, and recovery
Human Subjects/IRB Compliance. Sue Flynn Human Subject Compliance Manager
Human Subjects/IRB Compliance Sue Flynn Human Subject Compliance Manager Your Resources at the Broad Sue Flynn, Human Subjects Compliance Manager sflynn@broadinstitute.org or 714-7221 Jackie Murphy, Human
Use of IRB Quality Metrics for Performance Assurance of the Ethics Committee
Use of IRB Quality Metrics for Performance Assurance of the Ethics Committee Pornpimon Adams FTM-EC Secretary Faculty of Tropical Medicine, Mahidol University Background Ethics Committee Faculty of Tropical
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST Chairman, Medical Educa?on Sec?on, Medical Associa?on of Thailand
IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol
IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol Use this checklist to assemble your request for your institution s IBC to review a specific protocol. If WIRB does not already administer
Troubleshooting Informed Consent. Sandra Meadows, MPH, CIP Office of Responsible Research Practices June 26, 2018
Troubleshooting Informed Consent Sandra Meadows, MPH, CIP June 26, 2018 2 Session Objectives Identify common submission screening questions Examine IRB-required modifications related to the consent process
Outline of Discussion
This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are
Tip Sheet 17: Review of Research by the Expedited Procedure
Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure
The Institutional Review Board (IRB) Manual
The Institutional Review Board (IRB) Manual Investigational Devices Policy Research that involves the use of investigational devices must conform to Food and Drug Administration (FDA) and Department of
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
KPIs and Assessment: Developing Measures to Achieve Goals and Support Accountability
KPIs and Assessment: Developing Measures to Achieve Goals and Support Accountability Canadian Career Development Summit Kempenfelt Conference Centre April 12, 2017 Jan Basso Experiential Learning & Career
Human Subjects Research: IRB Resources
Research Compliance Office Human Subjects Research: IRB Resources Kristin B. Frazier HRPP Educational Specialist IRB Resources June 4, 2008 Topics Stanford Institutional Review Boards (IRB) Charge of IRB
Defining research compliance Protocol review committees Conflicts of interest Export Controls
Defining research compliance Protocol review committees Conflicts of interest Export Controls What is Research Compliance? Conformance with Federal, State, and Local Regulations and University Policies
The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
Crea%ng a Value Orienta%on & Ar%cula%ng the Impact. The Movement from Volume to Value
Crea%ng a Value Orienta%on & Ar%cula%ng the Impact The Movement from Volume to Value Ra2onale for Change to the Health Care System Be:er Care, Be:er Health, Lower Costs Ever rising health care costs are
H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS
H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).
Disruptive Innovation and the Future of Medicine: Are We Prepared?
Disruptive Innovation and the Future of Medicine: Are We Prepared? Carolyn Compton, MD, PhD Professor of Life Sciences, Arizona State University Professor of Laboratory Medicine and Pathology, Mayo Clinic
Introduc)on. High costs of food borne illness in Wisconsin. Threats to food safety compromise Wisconsin s agricultural industry (2007)
Introduc)on High costs of food borne illness in Wisconsin $2.9 billion in 2009 $516 per resident (Scharff, 2010) Threats to food safety compromise Wisconsin s agricultural industry (2007) $60 billion to
Protocol Submission Form
Protocol Submission Form 1. Administrative Information Name of Submitting Party: Street: Province/State: Postal/Zip Code: Phone: ( ) E-mail Address: Fax: ( ) Other: ( ) Date: 2. General Study Information
EuroNet- PHL- C2 trial set- up and trial monitoring
EuroNet- PHL- C2 trial set- up and trial monitoring Chris9ne Mauz- Körholz Department of Pediatrics Pediatric Hematology and Oncology UKGM, Justus- Liebig University of Gießen, Germany ScienCfic Secretary
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed
Beyond Auditing and Monitoring and Towards Quality Improvement
Beyond Auditing and Monitoring and Towards Quality Improvement HCCA CI 2019 John Baumann, PhD. Associate Vice President for Research Compliance Office of Research Compliance Vice President for Research
Module One: Produc.ve Management Methodology for Health Services (PMMHS) An Introduc.on Part 2
Module One: Produc.ve Management Methodology for Health Services (PMMHS) An Introduc.on Part 2 What is PMMHS? It is a methodology for the management of health services based on produc.on, efficiency, resources
11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
Division of Forestry
Division of Forestry Briefing for Wisconsin County Forest Associa5on September 29, 2017 Fred Souba, Jr. Division Administrator, Chief State Forester Mike Warnke Forestry Services Deputy Heather Berklund
1 of 5 11/6/2014 3:08 PM
1 of 5 11/6/2014 3:08 PM : Thursday, November 6, 2014 1:07:42 PM : NU SF: Basic Information 1. * Title of study: Biomedical Research Study 2. * Short title: Biomedical Study 3. * Brief description: This
Chapter 11 Objectives
1 Chapter 11 Objectives 1. Explain what strategic cost management is and how it can be used to help a firm create a compe99ve advantage. 2. Discuss value- chain analysis and the strategic role of ac9vity-
Sulfur Dioxide Emission, Economic Growth and Energy Efficiency: A Panel- Data Analysis for China
7 th AWEEE, A Toxa, Galicia 28 June 2016 Sulfur Dioxide Emission, Economic Growth and Energy Efficiency: A Panel- Data Analysis for China Bin Hu & Ross McKitrick Central University of Finance and Economics
Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form
Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. Demographic Information Date of Submission: Reason for Submission: New Project Response to Comments Reconsideration Disapproval
1 GENERAL INFORMATION FOR ALL IRB MEMBERS FOR CONVENED MEETINGS Information for Other Business items Educational Materials
HRP-301 8/15/2017 1 of 5 The purpose of this worksheet is to provide support for IRB staff who prepare review materials for convened IRB meetings or prepare materials for Non-Committee Review. This worksheet
11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device
Emergency Use of an Investigational Drug, Biologic or Device Introduction The emergency use provision in the FDA regulations (21 CFR 56.102d) is an exemption from prior review and approval by the IRB for
Waste Pes(cide Recovery Program in SC. Carolina Recycling Associa(on 1 April 2014 Asheville, NC
Waste Pes(cide Recovery Program in SC Carolina Recycling Associa(on 1 April 2014 Asheville, NC Topics to cover Review the state agencies regulatory responsibili(es pertaining to pes(cides Take a look
PHS Human Subjects and Clinical Trials Information
PHS Human Subjects and Clinical Trials Information OMB Number: 925-1 Expiration Date: 3/31/22 Please complete the human subjects section of the Research & Related Other Project Information form prior to
Kotler Keller. Marketing Management 14e
Phillip Kevin Lane Kotler Keller Marketing Management 14e Analyzing Business Markets Discussion Ques>ons 1. What is the business market, and how does it differ from the consumer market? 2. What buying
Disrup'ng the Status Quo of Reac've Pricing
Disrup'ng the Status Quo of Reac've Pricing Jeremy Pifer Director of Pricing Hologic: The Science of Sure Innova've healthcare company with market- leading products for early detec'on and interven'on,
8 Most Significant Proposed Changes to the Common Rule. Susan L. Rose Office for the Protection of Research Subjects (OPRS)
8 Most Significant Proposed Changes to the Common Rule Susan L. Rose Office for the Protection of Research Subjects (OPRS) Overview 1. Informed Consent 2. Use of Biospecimens 3. Activities Excluded from
Requirements for Humanitarian Use Device (HUD)
Requirements for Humanitarian Use Device (HUD) 1. Definition of Humanitarian Use Device - The definition of a HUD is a device that is intended to benefit patients in the treatment and diagnosis of diseases
Pla$orm for Engaging Everyone Responsibly (PEER)
Pla$orm for Engaging Everyone Responsibly (PEER) We begin with a novel perspec
Managed Care Readiness Training Series: Revenue Cycle Management 4th Learning Community Remi;ance, Appeals, Collec?
Managed Care Readiness Training Series: Revenue Cycle Management 4th Learning Community Remi;ance, Appeals, Collec?ons and Analysis Remi;ance, Appeals, Collec?on and Analysis Presenter: Boris Vilgorin,
MVP Access Program Access to Data and Sera collected during the MenAfriVac clinical trials
MVP Access Program Access to Data and Sera collected during the MenAfriVac clinical trials 23 February 2016 The MVP Closure Conference Lionel Martellet Clinical Opera0ons Manager Presenta;on Overview 1.
Study on Traceability of Fisheries Products
Study on Traceability of Fisheries Products A compara9ve study of 10 country cases under the framework of the programme GCP/INT/253/JPN Francisco Blaha Melania Borit, Ph.D and Kim Thompson Objec9ve The
Ethics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
The European Spalla.on Source Business Opportuni.es. Luis Ortega Procurement Officer
The European Spalla.on Source Business Opportuni.es Luis Ortega Procurement Officer www.europeanspalla.onsource.se 29 April 2015 Topics Industry and ESS Business Opportuni.es ESS Procurement ESS In- kind
Modelling Collec,ve Commons Problems: Future Scenarios for P2P Money
Modelling Collec,ve Commons Problems: Future Scenarios for P2P Money David Hales, University of Szeged, Hungary www.davidhales.com Diversity in Macro Conf. Feb 24-25 th 2014 University of Essex Who am
Human Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
Produce Safety Network
Produce Safety Network PSN Outreach & Regulatory Infrastructure March 14, 2018 Diane Ducharme Nicole Clausen Produce Safety Network Southern Region 1 Forma
Title: Review of Medical Devices Page: 1 of 5 Written by:
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,
Advancing Clinical and Transla/onal Research with Informa/cs at the University of Kansas Medical Center
Advancing Clinical and Transla/onal Research with Informa/cs at the University of Kansas Medical Center Russ Waitman, PhD Director of Medical Informa1cs, Associate Professor, Department of Biosta1s1cs
University of Rochester
University of Rochester Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. General Information Reason for Submission to ESCRO: New Project Response to Comments Reconsideration
Collaboration and Efficiency in IRB review of Multi-Site Research
Collaboration and Efficiency in IRB review of Multi-Site Research Human Subject Research Community Conference University of Miami Student Activities Center (SAC) September 11, 2014 Cynthia Hahn VP, Clinical
NC Educa)on Cloud Internet2 Member Mee)ng October 4, 2011
NC Educa)on Cloud Internet2 Member Mee)ng October 4, 2011 1 Agenda History/Background about NC Educa8on Cloud Cloud Projects Overview and Status Updates General Q&A 2 About the NC Educa)on Cloud The NC
1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
Ethical Considera0ons. Scien0fic Responsibility. Scien0fic Responsibility. History Ethical Guidelines Animal Research
Ethical Considera0ons History Ethical Guidelines Animal Research Scien0fic Responsibility Researchers power over subjects Young students uncertain of their rights Trust in the integrity of the scien0st
Transla)ng Corporate Success for the Nonprofit Sector: Crea)ng a Balanced Scorecard for Integrated Fundraising Success
Transla)ng Corporate Success for the Nonprofit Sector: Crea)ng a Balanced Scorecard for Integrated Fundraising Success January 30, 2014 4:15-5:15pm Eastern Speakers: Mark Lukowski, CEO, Chris)an Children's
Monitoring- based Commissioning: Con2nuous Performance Inves2ga2on and Evalua2on
Monitoring- based Commissioning: Con2nuous Performance Inves2ga2on and Evalua2on Jessica Granderson PhD Lawrence Berkeley Na2onal Laboratory Energy Informa2on Systems and the Energy Informa-on Handbook
NIH Forms E Changes for Human Subject and/or Clinical Trial Applications Attached are the Forms E application pages with the most significant changes
NIH Forms E Changes for Human Subject and/or Clinical Trial Applications Attached are the Forms E application pages with the most significant changes (pages 11-16). Many of the new fields require a short
Update on Japan s Regulation of Cell-Based Therapeutic Products
NIHS Since 1874 Stem Cell & Regenerative Medicine Global Congress 2016 August 23, 2016 Gyeonggi-do, Korea Update on Japan s Regulation of Cell-Based Therapeutic Products Yoji Sato, Ph.D. Head, Division
PARTNERS HUMAN RESEARCH COMMITTEE. Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review
PARTNERS HUMAN RESEARCH COMMITTEE Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review For the purposes of this Primer, tissue is defined as any biological specimen obtained
The Presentation Will Begin At 12PM EST. Process Design: Problem Management Graham Furnis, Senior Consultant B Wyze Solutions
The Presentation Will Begin At 12PM EST Process Design: Problem Management Graham Furnis, Senior Consultant B Wyze Solutions Helping you to achieve breakthroughs in your organization! Templates Live Webinars
Responding to a Crisis
Memorial University of Newfoundland Responding to a Crisis Managing Quality with Nestle India Edge Consul;ng Agenda Problem Statement Neal What should have happened Key Issues Key Objec;ves Alterna;ves
Integra:ng the Cost of Quality into Laboratory Opera:ons BIO- RAD LABORATORIES QUALITY SYSTEMS DIVISION
Integra:ng the Cost of Quality into Laboratory Opera:ons BIORAD LABORATORIES QUALITY SYSTEMS DIVISION Anne T. Daley Daley Consul,ng, LLC Mesa, AZ INCORPORATING THE COST OF QUALITY INTO BUDGET DISCUSSIONS
To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission
Help Your Account Holders Instantly Fund & Switch Their Primary Account to Your Financial Ins<tu<on
Presentation and video replay will be provided within one week. Have questions? Use the questions panel - we ll field them as we go and during the Q&A recap Help Your Account Holders Instantly Fund & Switch
Institutional Review Board Compliance Elizabeth City State University
Institutional Review Board Compliance Elizabeth City State University Michelle Moore, MBA Research Compliance Officer/IRB Administrator Office of Sponsored Programs, Contracts & Grants 110 McLendon Hall
POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 Research investigating or evaluating drugs, biologics or devices must
Performance Plan Training 2018
Performance Plan Training 2018 Agenda Key Policy Changes Roles & Responsibili6es Timeline Ins6tu6onal Goals Individual Goals Performance Discussion Scoring & Tips Key Policy Changes Performance Cycle Work
Splunking IT Data Is Great, Splunking Non- IT Data Is Awesome
Copyright 2015 Splunk Inc. Splunking IT Data Is Great, Splunking Non- IT Data Is Awesome Mathew Benwell Informa?on Security Specialist, The University of Adelaide Disclaimer During the course of this presenta?on,
Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual.
Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual Table of Contents A. Charge of the Committee (IBC)... 2 B. Membership.....2 C. Committee
Performance Management Informa/on Session
Performance Management Informa/on Session Objec/ves Timelines Iden+fy components of performance management program Describe the difference between individual and ins+tu+onal goals Next Steps The 2017-2018
AASBO May /1/17. Posi*on Control as a Management Tool. Posi2on Control Basics Master Posi2on
AASBO May 2017 Posi*on Control as a Management Tool Objec2ves of Posi2on Control Ensure that all Employees are Assigned to Authorized and Funded Posi*ons Streamline Workflow Between HR and PR Eliminate
METRICS THAT MATTER: ASSESSING WORKFLOW AND STAFFING
METRICS THAT MATTER: ASSESSING WORKFLOW AND STAFFING Michele Vaughan, BS, CCRP Research Strategy and Compliance Specialist Nationwide Children s Hospital, Columbus, OH Susan Sedwick, PhD, CRA, CSM Senior
State of the Union Presenta/on Template
State of the Union Presenta/on Template This presentation includes the guidelines for a church s retreat presentation. Each bullet represents potentially a separate slide in the final presentation Where
Conducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
T his presen ta o n can be do w n lo aded at
i T his presen ta o n can be do w n lo aded at w w w.o spe.o n.ca/ presen ta o n s 2 Outline of Presenta$on ² Data Sources for Today s Presenta,on ² Fundamental goal of CPD programs ² Stand alone CPD versus
Administrative Policies VMC #638.1 and Procedures Manual
Administrative Policies VMC #638.1 and Procedures Manual January 14, 2013 TO: FROM: SUBJECT: REFERENCE: VMC Employees Paul E. Lorenz Chief Executive Officer, SCVMC Research Involving Human Subjects TJC,
4.1. Target Accrual Rate: The Target Accrual Goal divided by the Expected Duration (in days) of the trial.
POLICY #: COM-102 Page: 1 of 5 1. POLICY STATEMENT: The Scientific Review Committee (SRC) is responsible for monitoring the accrual and evaluating the scientific merit of each interventional clinical research
US Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
Guaranteed Energy Savings Performance Contrac7ng State Program. October 27, 2011
Guaranteed Energy Savings Performance Contrac7ng State Program October 27, 2011 Energy Services Coali7on The Energy Services Coali7on (ESC) is a na7onal nonprofit organiza7on composed of a network of experts
Streamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
Biomass Success & Challenges in Public Ins5tu5ons in the Northeast U.S.
Biomass Success & Challenges in Public Ins5tu5ons in the Northeast U.S. Jeremy Mortl engineering@burnchips.com www.burnchips.com History of Messersmith Manufacturing Messersmith Manufacturing was incorporated
13.0 Quality Improvement in the HRPP Program
13.0 Quality Improvement in the HRPP Program 13.1 Definitions Quality Improvement: A process initiated to develop/enhance a practice or procedure and to institutionalize the practice or procedure. Audit: